Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kongtim, Piyanuch  [Clear All Filters]
2019
Srour, S.A., Saliba, R.M., Bittencourt, M.Cb, Perez, J.Miguel Ram, Kongtim, P., Alousi, A., Al-Atrash, G., Olson, A., Betul, O., Mehta, R., et al. (2019). Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.
Kongtim, P., Hasan, O., Perez, J.Miguel Ram, Varma, A., Wang, S.A., Patel, K.P., Chen, J., Rondon, G., Srour, S., Bashir, Q., et al. (2019). A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.
2016
Kongtim, P., Cao, K., and Ciurea, S.O. (2016). Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation.Adv Hematol2016, 4025073.
Gaballa, S., Ge, I., Fakih, R.El, Brammer, J.E., Kongtim, P., Tomuleasa, C., Wang, S.A., Lee, D., Petropoulos, D., Cao, K., et al. (2016). Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.
2015
Kongtim, P., Lee, D.A., Cooper, L.J.N., Kebriaei, P., Champlin, R.E., and Ciurea, S.O. (2015). Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy.Biol Blood Marrow Transplant.